BACKGROUND: Spontaneous bacterial peritonitis (SBP) is the most prevalent bacterial infection in patients with cirrhosis. Although studies from Europe have reported significant rates of resistance to third-generation cephalosporins, there are limited SBP-specific data from centres in North America. OBJECTIVE: To evaluate the prevalence of, predictors for and clinical impact of third-generation cephalosporin-resistant SBP at a Canadian tertiary care centre, and to summarize the data in the context of the existing literature. METHODS: SBP patients treated with both antibiotics and albumin therapy at a Canadian tertiary care hospital between 2003 and 2011 were retrospectively identified. Multivariate logistic regression was used to determine independent predictors of third-generation cephalosporin resistance and mortality. RESULTS: In 192 patients, 25% of infections were nosocomial. Forty per cent (77 of 192) of infections were culture positive; of these, 19% (15 of 77) were resistant to third-generation cephalosporins. The prevalence of cephalosporin resistance was 8% with community-acquired infections, 17% with health care-associated infections and 41% with nosocomial acquisition. Nosocomial acquisition of infection was the only predictor of resistance to third-generation cephalosporins (OR 4.0 [95% CI 1.04 to 15.2]). Thirty-day mortality censored for liver transplantation was 27% (50 of 184). In the 77 culture-positive patients, resistance to third-generation cephalosporins (OR 5.3 [1.3 to 22]) and the Model for End-stage Live Disease score (OR 1.14 [1.04 to 1.24]) were independent predictors of 30-day mortality. CONCLUSIONS: Third-generation cephalosporin-resistant SBP is a common diagnosis and has an effect on clinical outcomes. In an attempt to reduce the mortality associated with resistance to empirical therapy, high-risk subgroups should receive broader empirical antibiotic coverage.
BACKGROUND: Spontaneous bacterial peritonitis (SBP) is the most prevalent bacterial infection in patients with cirrhosis. Although studies from Europe have reported significant rates of resistance to third-generation cephalosporins, there are limited SBP-specific data from centres in North America. OBJECTIVE: To evaluate the prevalence of, predictors for and clinical impact of third-generation cephalosporin-resistant SBP at a Canadian tertiary care centre, and to summarize the data in the context of the existing literature. METHODS: SBP patients treated with both antibiotics and albumin therapy at a Canadian tertiary care hospital between 2003 and 2011 were retrospectively identified. Multivariate logistic regression was used to determine independent predictors of third-generation cephalosporin resistance and mortality. RESULTS: In 192 patients, 25% of infections were nosocomial. Forty per cent (77 of 192) of infections were culture positive; of these, 19% (15 of 77) were resistant to third-generation cephalosporins. The prevalence of cephalosporin resistance was 8% with community-acquired infections, 17% with health care-associated infections and 41% with nosocomial acquisition. Nosocomial acquisition of infection was the only predictor of resistance to third-generation cephalosporins (OR 4.0 [95% CI 1.04 to 15.2]). Thirty-day mortality censored for liver transplantation was 27% (50 of 184). In the 77 culture-positive patients, resistance to third-generation cephalosporins (OR 5.3 [1.3 to 22]) and the Model for End-stage Live Disease score (OR 1.14 [1.04 to 1.24]) were independent predictors of 30-day mortality. CONCLUSIONS: Third-generation cephalosporin-resistant SBP is a common diagnosis and has an effect on clinical outcomes. In an attempt to reduce the mortality associated with resistance to empirical therapy, high-risk subgroups should receive broader empirical antibiotic coverage.
Authors: Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo Journal: Hepatology Date: 2012-04-04 Impact factor: 17.425
Authors: Jeong Heo; Yeon Seok Seo; Hyung Joon Yim; Taeho Hahn; Sang Hoon Park; Sang Hoon Ahn; Jun Yong Park; Ji Young Park; Moon Young Kim; Sung Keun Park; Mong Cho; Soon Ho Um; Kwang Hyub Han; Hong Soo Kim; Soon Koo Baik; Byung Ik Kim; Se Hyun Cho Journal: Gut Liver Date: 2009-09-30 Impact factor: 4.519
Authors: S Khumra; J Chan; K Urbancic; T Worland; P Angus; R Jones; M L Grayson; J A Trubiano Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Raquel Pimentel; Jorge Leitão; Carlos Gregório; Lélita Santos; Armando Carvalho; Pedro Figueiredo Journal: GE Port J Gastroenterol Date: 2021-08-24
Authors: Isabel Legaz; Jose M Bolarin; Jose A Campillo; Rosa M Moya; Aurelio Luna; Eduardo Osuna; Alfredo Minguela; Francisco Sanchez-Bueno; Maria Rocio Alvarez; Manuel Muro Journal: Arch Med Sci Date: 2019-06-18 Impact factor: 3.318
Authors: Marco Fiore; Alberto Enrico Maraolo; Ivan Gentile; Guglielmo Borgia; Sebastiano Leone; Pasquale Sansone; Maria Beatrice Passavanti; Caterina Aurilio; Maria Caterina Pace Journal: World J Gastroenterol Date: 2017-07-07 Impact factor: 5.742
Authors: Marco Fiore; Alberto Enrico Maraolo; Ivan Gentile; Guglielmo Borgia; Sebastiano Leone; Pasquale Sansone; Maria Beatrice Passavanti; Caterina Aurilio; Maria Caterina Pace Journal: World J Hepatol Date: 2017-10-28